Tambussi G, Repetto L, Torri V, Saracco A, Moresco L, Antinori A, Zerboni R, Lazzarin A
Department of Infectious Diseases, Mario Negri Institute, Milan, Italy.
Ann Oncol. 1995 Apr;6(4):383-7. doi: 10.1093/oxfordjournals.annonc.a059188.
We wished to assess the clinical value in terms of treatment choice and establishment of the prognosis of the ACTG classification modified (TNM-TIS) according to the recent guidelines of CDC for the classification of the HIV infection in patients with HIV-related epidemic Kaposi's sarcoma (EKS).
We retrospectively studied 296 HIV-positive individuals with EKS. Patients were initially classified according to the NYU system and then reclassified according to the TNM-TIS proposal which considers three major parameters: T, anatomical extent of the lesion; I, immune system status; S, HIV-related systemic illness.
Survival analyses according to patient characteristics and the different TNM-TIS classification stages were performed; curves were compared using the Kaplan-Meyer method, and predictive factors for survival using the Cox model.
Of the parameters considered in the TNM-TIS staging system, the T variable was not predictive of survival. Conversely, I and S variables revealed predictive value in the survival analyses, when considered separately and together.
The extent of cutaneous or mucosal lesions of Kaposi's sarcoma did not correlate with prognosis. However, both CD4+ cell count and history of systemic illness were predictive of survival. Indicators of HIV infection must be included in the clinical evaluation of EKS patients and taken into account when choosing optimal treatment.
我们希望根据美国疾病控制与预防中心(CDC)关于人类免疫缺陷病毒(HIV)相关流行性卡波西肉瘤(EKS)患者HIV感染分类的最新指南,评估改良的ACTG分类(TNM-TIS)在治疗选择和预后判定方面的临床价值。
我们回顾性研究了296例HIV阳性的EKS患者。患者最初根据纽约大学系统进行分类,然后根据TNM-TIS方案重新分类,该方案考虑三个主要参数:T,病变的解剖范围;I,免疫系统状态;S,HIV相关的全身性疾病。
根据患者特征和不同的TNM-TIS分类阶段进行生存分析;使用Kaplan-Meyer方法比较曲线,并使用Cox模型分析生存的预测因素。
在TNM-TIS分期系统所考虑的参数中,T变量不能预测生存。相反,I和S变量在单独和综合考虑时,在生存分析中均显示出预测价值。
卡波西肉瘤皮肤或黏膜病变的范围与预后无关。然而,CD4+细胞计数和全身性疾病史均能预测生存。HIV感染指标必须纳入EKS患者的临床评估中,并在选择最佳治疗方案时予以考虑。